Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 88 of 173 for:    pertuzumab

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03726879
Recruitment Status : Recruiting
First Posted : November 1, 2018
Last Update Posted : November 1, 2019
Sponsor:
Collaborator:
Chugai Pharmaceutical
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab compared with placebo when given in combination with neoadjuvant dose-dense anthracycline (doxorubicin) + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab (ddAC-PacHP) in patients with early HER2-positive breast cancer (T2-4, N1-3, M0).

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Atezolizumab Drug: Placebo Drug: Doxorubicin Drug: Cyclophosphamide Drug: Paclitaxel Drug: Trastuzumab Drug: Pertuzumab Drug: Trastuzumab Emtansine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 453 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Actual Study Start Date : January 11, 2019
Estimated Primary Completion Date : April 21, 2021
Estimated Study Completion Date : September 20, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Atezolizumab +ddAC-PacHP
Participants will receive atezolizumab 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV), followed by atezolizumab 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with an initial 8-mg/kg IV loading dose) Q3W for 4 cycles, and pertuzumab 420 mg IV (with an initial 840-mg IV loading dose) Q3W for 4 cycles. During the adjuvant phase, participants will continue to receive the following study treatments Q3W to complete up to 1 year of HER2-target therapy inclusive of therapy given both in the neoadjuvant and adjuvant setting: atezolizumab 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with an initial 8-mg/kg IV loading dose) Q3W, and pertuzumab 420 mg IV (with an initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have the option of receiving blinded atezolizumab + trastuzumab emtansine post surgery for 14 cycles.
Drug: Atezolizumab
Atezolizumab will be administered as per the schedule specified in the respective arm.
Other Name: Tecentriq

Drug: Doxorubicin
Doxorubicin will be administered as per the schedule specified in the respective arm.
Other Name: Adriamycin

Drug: Cyclophosphamide
Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Other Names:
  • Cytoxan
  • Neosar

Drug: Paclitaxel
Paclitaxel will be administered as per the schedule specified in the respective arm.
Other Name: Taxol

Drug: Trastuzumab
Trastuzumab will be administered as per the schedule specified in the respective arm.
Other Name: Herceptin

Drug: Pertuzumab
Pertuzumab will be administered as per the schedule specified in the respective arm.
Other Name: Perjeta

Drug: Trastuzumab Emtansine
Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
Other Name: Kadcyla

Placebo Comparator: Placebo + ddAC-PacHP
Participants will receive placebo 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV), followed by placebo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with an initial 8-mg/kg IV loading dose) Q3W for 4 cycles, and pertuzumab 420 mg IV (with an initial 840-mg IV loading dose) Q3W for 4 cycles. During the adjuvant phase, participants will continue to receive the following study treatments Q3W to complete up to 1 year of HER2-target therapy inclusive of therapy given both in the neoadjuvant and adjuvant setting: placebo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with an initial 8-mg/kg IV loading dose) Q3W, and pertuzumab 420 mg IV (with an initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have the option of receiving blinded atezolizumab + trastuzumab emtansine post surgery for 14 cycles.
Drug: Placebo
Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.

Drug: Doxorubicin
Doxorubicin will be administered as per the schedule specified in the respective arm.
Other Name: Adriamycin

Drug: Cyclophosphamide
Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Other Names:
  • Cytoxan
  • Neosar

Drug: Paclitaxel
Paclitaxel will be administered as per the schedule specified in the respective arm.
Other Name: Taxol

Drug: Trastuzumab
Trastuzumab will be administered as per the schedule specified in the respective arm.
Other Name: Herceptin

Drug: Pertuzumab
Pertuzumab will be administered as per the schedule specified in the respective arm.
Other Name: Perjeta

Drug: Trastuzumab Emtansine
Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
Other Name: Kadcyla




Primary Outcome Measures :
  1. Percentage of Participants with Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3) [ Time Frame: From randomization to approximately 24 months ]
    pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (NAST) (i.e., ypT0/is ypN0 in the current American Joint Committee on Cancer [AJCC] staging system, 8th edition).

  2. pCR in the ITT Population [ Time Frame: From randomization to approximately 24 months ]

Secondary Outcome Measures :
  1. Percentage of Participants with pCR Based on Hormone Receptor Status [ Time Frame: From randomization to approximately 24 months ]
    pCR (ypT0/is ypN0) based upon hormone receptor status (estrogen receptor [ER]/progesterone receptor [PgR] positive or ER/PgR negative).

  2. Percentage of Participants with pCR in the PD-L1-Negative Population [ Time Frame: From randomization to approximately 24 months ]
    pCR (ypT0/is ypN0) in the IC 0 Population

  3. Event-Free Survival (EFS) [ Time Frame: From randomization to first documented disease recurrence, unequivocal tumor progression determined by the treating investigator, or death from any cause (up to approximately 54 months) ]
    EFS defined as the time from randomization to the first documented disease recurrence, unequivocal tumor progression determined by the treating investigator, or death from any cause, whichever occurs first, in all patients and based upon hormone receptor status (ER/PgR positive or ER/PgR negative) and PD-L1 status (IC 0; IC 1/2/3).

  4. Disease-Free Survival (DFS) [ Time Frame: Time from surgery to first documented disease recurrence or death from any cause (up to approximately 54 months) ]
    DFS defined as the time from surgery to the first documented disease recurrence or death from any cause, whichever occurs first, in all patients who undergo surgery and based upon hormone receptor status (ER/PgR positive or ER/PgR negative) and PD-L1 status (IC 0; IC 1/2/3).

  5. Overall Survival (OS) [ Time Frame: From randomization to date of death from any cause (up to approximately 54 months) ]
    OS defined as the time from randomization to death from any cause in all patients and based upon hormone receptor status (ER/PgR positive or ER/PgR negative) and PD-L1 status (IC 0; IC 1/2/3).

  6. Mean Changes From Baseline in Function (Role, Physical) [ Time Frame: Baseline; Day 1 of Cycle 1-9, on Day 1 of every other cycle thereafter until Cycle 22; at the treatment discontinuation or early termination visit and follow up visit. Cycle 1-4, each cycle is 14 days. Cycle 5-22, each cycle is 21 days. ]
    Mean changes from baseline score in function (role, physical) will be assessed by the functional scales of EORTC QLQ-C30.

  7. Mean Changes From Baseline in Global Health Status [ Time Frame: Baseline; Day 1 of Cycle 1-9, on Day 1 of every other cycle thereafter until Cycle 22; at the treatment discontinuation or early termination visit and follow up visit. Cycle 1-4, each cycle is 14 days. Cycle 5-22, each cycle is 21 days. ]
    Mean changes from baseline will be assessed by the GHC/HRQoL scales of the EORTC QLQ-C30.

  8. Percentage of Participants With Adverse Events [ Time Frame: Baseline to end of study (approximately 54 months) ]
  9. Maximum Serum Concentration (Cmax) of Atezolizumab [ Time Frame: Day 1 of Cycle 1, 2, 3, 4, 8, 12, 16, at treatment discontinuation visit. Cycle 1-4, each cycle is 14 days. Cycle 8-16, each cycle is 21 days. ]
    Cmax is the maximum (or peak) concentration that a study drug achieves in the body.

  10. Minimum Serum Concentration (Cmin) of Atezolizumab [ Time Frame: Day 1 of Cycle 1, 2, 3, 4, 8, 12, 16, at treatment discontinuation visit. Cycle 1-4, each cycle is 14 days. Cycle 8-16, each cycle is 21 days. ]
    Cmin is the minimum (or trough) concentration that a study drug achieves in the body.

  11. Trough Concentration (Ctrough) for Pertuzumab and Trastuzumab in Serum [ Time Frame: Day 1 of Cycle 1, 8, 12, and at treatment discontinuation visit. Cycle 1-4, each cycle is 14 days. Cycle 8-12, each cycle is 21 days. ]
  12. Maximum Serum Concentration (Cmax) of Trastuzumab Emtansine in Serum [ Time Frame: Day 1 of Cycle 9 and Cycle 12, at treatment disontinuation visit. Cycle 9 and 12 are each 21 days. ]
  13. Minimum Serum Concentration (Cmin) of Trastuzumab Emtansine in Serum [ Time Frame: Day 1 of Cycle 9 and Cycle 12, at treatment disontinuation visit. Cycle 9 and 12 are each 21 days. ]
  14. Percentage of Participants with Treatment-Emergent Anti-Drug Antibodies (ADAs) to Atezolizumab [ Time Frame: Day 1 of Cycle 1, 2, 3, 4, 8, 12, 16, at treatment discontinuation visit. Cycle 1-4, each cycle is 14 days. Cycle 8-16, each cycle is 21 days. ]
  15. Percentage of Participants with Treatment-Emergent Anti-Drug Antibodies (ADAs) to Trastuzumab [ Time Frame: Day 1 of Cycle 1, 8, 12 and at treatment discontinuation visit. Cycle 1-4, each cycle is 14 days. Cycle 8-12, each cycle is 21 days. ]
  16. Percentage of Participants with Treatment-Emergent Anti-Drug Antibodies (ADAs) to Pertuzumab [ Time Frame: Day 1 of Cycle 1, 8, 12, and at treatment discontinuation visit. Cycle 1-4, each cycle is 14 days. Cycle 8-12, each cycle is 21 days. ]
  17. Percentage of Participants with Treatment-Emergent Anti-Drug Antibodies (ADAs) to Trastuzumab Emtansine [ Time Frame: Day 1 of Cycle 9 and Cycle 12, at treatment disontinuation visit. Cycle 9 and 12 are each 21 days. ]
  18. Percentage of Particpants with pCR Based on PIK3CA Mutation Status [ Time Frame: From randomization to approximately 24 months ]
  19. EFS Based on PIK3CA Mutation Status [ Time Frame: From randomization to first documented disease recurrence, unequivocal tumor progression determined by the treating investigator, or death from any cause (up to approximately 54 months) ]
  20. DFS Based on PIK3CA Mutation Status [ Time Frame: Time from surgery to first documented disease recurrence or death from any cause (up to approximately 54 months) ]
  21. OS Based on PIK3CA Mutation Status [ Time Frame: From randomization to date of death from any cause (up to approximately 54 months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed diagnosis of HER2-positive breast cancer, and hormonal and PD-L1 status, as documented through central testing of a representative tumor tissue specimen
  • Primary breast tumor size of > 2 cm by any radiographic measurement
  • Stage at presentation: T2-T4, N1-N3, M0 as determined by AJCC staging system, 8th edition
  • Pathologic confirmation of nodal involvement with malignancy must be determined by fine needle aspiration or core-needle biopsy. Surgical excision of lymph nodes is not permitted.
  • Patients with multifocal tumors are eligible provided at least one focus is sampled and centrally confirmed as HER2-positive.
  • Patients with multicentric tumors are eligible provided all discrete lesions are sampled and centrally confirmed as HER2-positive.
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Baseline LVEF >= 55% measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans
  • Adequate hematologic and end-organ function obtained within 14 days prior to initiation of study treatment
  • For women of childbearing potential: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating eggs
  • For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm
  • For patients enrolled in the extended China enrollment phase: current resident of mainland China and of Chinese ancestry (the China subpopulation will consist of patients enrolled at sites in mainland China and Taiwan who are of Chinese ancestry)

Exclusion Criteria:

  • Prior history of invasive breast cancer
  • Stage IV (metastatic) breast cancer
  • Patients with synchronous bilateral invasive breast cancer
  • Prior systemic therapy for treatment of breast cancer
  • Previous therapy with anthracyclines or taxanes for any malignancy
  • Ulcerating or inflammatory breast cancer
  • Undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes
  • Sentinel lymph node procedure or axillary lymph node dissection prior to initiation of neoadjuvant therapy
  • History of other malignancy within 5 years prior to screening, with the exception of those patients who have a negligible risk of metastasis or death
  • Cardiopulmonary dysfunction
  • Dyspnea at rest
  • Active or history of autoimmune disease or immune deficiency
  • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab/placebo, 6 months after the final dose of doxorubicin, 12 months after the final dose of cyclophosphamide, 6 months after the final dose of paclitaxel, or 7 months after the final dose of trastuzumab, pertuzumab, or trastuzumab emtansine whichever occurs last

Exclusion Criteria Related to Trastuzumab Emtansine in the Adjuvant Setting:

  • Patients who achieved pCR
  • Evidence of clinically evident gross residual or recurrent disease following neoadjuvant therapy and surgery
  • Unable to complete surgery with curative intent after conclusion of neoadjuvant systemic therapy
  • Patient discontinued treatment with trastuzumab because of toxicity during the neoadjuvant phase of the study
  • Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, or sclerosis cholangitis
  • Patients with Grade >=2 peripheral neuropathy
  • Prior treatment with trastuzumab emtansine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03726879


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: BO40747 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

  Show 96 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Chugai Pharmaceutical
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03726879     History of Changes
Other Study ID Numbers: BO40747
First Posted: November 1, 2018    Key Record Dates
Last Update Posted: November 1, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pertuzumab
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Maytansine
Ado-trastuzumab emtansine
Albumin-Bound Paclitaxel
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Trastuzumab
Atezolizumab
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists
Antibiotics, Antineoplastic